• Capricor Therapeutics reported second-quarter 2026 results on August 13, 2026, with net loss rising to US$40.73 million and basic and diluted loss per share from continuing operations at US$0.70, compared with US$25.91 million and US$0.57 a year earlier.
• Over the first half of 2026, the company’s net loss widened to US$74.67 million and loss per share to US$1.29, underscoring intensifying cost pressures as it advances its pipeline.
• We’ll now examine how this widening quarterly net loss affects Capricor’s earlier investment narrative around pipeline potential and regulatory milestones.

Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Capricor Therapeutics Investment Narrative Recap

To own Capricor today, you need to believe that Deramiocel can clear its current regulatory hurdles and eventually support a viable commercial business, despite zero revenue and mounting losses. The wider Q2 and first half 2026 net loss reinforces that the near term story is still about the upcoming FDA decision on Deramiocel, while the biggest risk remains that continued setbacks or delays, combined with rising cash burn, could increase financing needs and dilute existing shareholders.

In that context, the recent FDA advisory committee vote against sufficient evidence of efficacy for Deramiocel, despite positive HOPE 3 data and a pending PDUFA action date, is highly relevant to these results. It reinforces how dependent the company remains on one unapproved asset to eventually offset deepening operating losses, and why regulatory decisions around Deramiocel are likely to matter more to the long term thesis than quarter to quarter earnings volatility.

Yet against the promise of Deramiocel, the combination of deeper first half losses and ongoing regulatory uncertainty is a risk investors should be aware of, because...

Capricor Therapeutics' narrative projects $156.1 million revenue and $25.4 million earnings by 2029.

Uncover how Capricor Therapeutics' forecasts yield a $4.38 fair value, a 34% downside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already cautious, assuming revenue of about US$114.5 million and earnings of roughly US$32.5 million by 2029, and this quarter’s bigger loss may push that more pessimistic view further, so it is worth comparing those expectations with your own.

Explore 6 other fair value estimates on Capricor Therapeutics - why the stock might be a potential multi-bagger!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Capricor Therapeutics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Capricor Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Capricor Therapeutics' overall financial health at a glance.

Want Some Alternatives?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 50 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.